INCIVEK Drug Patent Profile

When do Incivek patents expire, and what generic alternatives are available?

Incivek is a drug marketed by Vertex Pharms and is included in one NDA. There is one patent protecting this drug.

This drug has nineteen patent family members in twelve countries.

The generic ingredient in INCIVEK is telaprevir. There are three drug master file entries for this compound. Additional details are available on the telaprevir profile page.

DrugPatentWatch^® Generic Entry Outlook for Incivek

Incivek was eligible for patent challenges on May 23, 2015.

By analyzing the patents and regulatory protections it appears that the earliest date for generic entry will be May 30, 2028. This may change due to patent challenges or generic licensing.

Indicators of Generic Entry

Summary for INCIVEK

International Patents:	19
US Patents:	1
Applicants:	1
NDAs:	1

US Patents and Regulatory Information for INCIVEK

INCIVEK is protected by one US patents.

This potential generic entry date is based on patent 8,431,615.

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Vertex Pharms	INCIVEK	telaprevir	TABLET;ORAL	201917-001	May 23, 2011		DISCN	No	No	8,431,615

International Patents for INCIVEK

See the table below for patents covering INCIVEK around the world.

Country	Patent Number	Title	Estimated Expiration
Spain	2325481
Norway	20072733
Japan	2013060474	DOSE FORMS COMPRISING VX-950 AND THEIR DOSAGE REGIMEN
New Zealand	569670	Peptidomimetic protease inhibitors particular for the NS3 protease of Hepatitis C and act synergistically with anti-Hepatitis C compounds
European Patent Office	2368901
China	1869061

Supplementary Protection Certificates for INCIVEK

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1320540	SPC/GB12/010	United Kingdom		PRODUCT NAME: TELAPREVIR OR PHARMACEUTICALLY ACCEPTABLE SALTS AND/OR SOLVATES OF TELAPREVIR OR SOLVATES OF SUCH SALTS.; REGISTERED: UK EU/1/11/720/001 20110919
1320540	122012000015	Germany		PRODUCT NAME: TELAPREVIR UND JEDE THERAPEUTISCH AEQUIVALENTE FORM DAVON, WELCHE DURCH DAS GRUNDPATENT GESCHUETZT IST, WIE PHARMAZEUTISCH VERTRAEGLICHE SALZE UND/ODER SOLVATE VON TELAPREVIR ODER SOLVATE SOLCHER SALZE.; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
1320540	CA 2012 00007	Denmark
1320540	C 2012 005	Romania		PRODUCT NAME: TELAPREVIR SI TOATE FORMELE ECHIVALENTE TERAPEUTIC ALEACESTUIA, PRECUM SARURI SI/SAU SOLVATI ACCEPTABILI FARMACEUTIC SAU SOLVATI AI UNOR ASTFEL DE SARURI; NATIONAL AUTHORISATION NUMBER: RO EU/1/11/720/001; DATE OF NATIONAL AUTHORISATION: 20110919; NUMBER OF FIRST AUTHORISATION IN EUROPEAN ECONOMIC AREA (EEA): EU/1/11/720/001; DATE OF FIRST AUTHORISATION IN EEA: 20110919
1320540	2012/009	Ireland		PRODUCT NAME: TELAPREVIR, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT AND/OR SOLVATE THEREOF OR SOLVATES OF SUCH SALTS; REGISTRATION NO/DATE: EU/1/11/720/001 20110919
1320540	132012902033336	Italy		PRODUCT NAME: TELAPREVIR(TELAPREVIR); AUTHORISATION NUMBER(S) AND DATE(S): EU/1/11/720/001, 20110919

Investment Scenario, Market Dynamics, and Financial Trajectory for INCIVEK (Telaprevir)

Last updated: February 3, 2026

Summary

INCIVEK (telaprevir) is an oral protease inhibitor developed for the treatment of hepatitis C virus (HCV) infection. Initially approved by the U.S. Food and Drug Administration (FDA) in 2011, it represented a significant advance in direct-acting antiviral (DAA) therapy. However, subsequent shifts in the HCV treatment landscape, notably the advent of highly effective, all-oral, interferon-free regimens, substantially impacted INCIVEK's market share. This analysis explores its current investment scenario, market dynamics, and financial trajectory, offering a comprehensive view of its positioning within the pharmaceutical landscape.

---

1. Overview of INCIVEK (Telaprevir) and Its Therapeutic Profile

Attribute	Details
Generic Name	Telaprevir
Brand Name	INCIVEK (withdrawn from market as of 2014)
Therapeutic Class	Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor
Approved Indication	Chronic HCV Genotype 1 infection in combination with peginterferon alfa and ribavirin
Mechanism of Action	Inhibits HCV NS3/4A protease, essential for viral replication

Note: Telaprevir was withdrawn from the market by its developer, Vertex Pharmaceuticals, in 2014, primarily due to declining sales following the introduction of newer therapies.

---

2. Market Dynamics in the HCV Therapeutics Landscape

A. Initial Market Introduction (2011–2013)

• Market Penetration: Rapid adoption following FDA approval, driven by the need for more effective HCV treatments.
• Peak Sales: Estimated revenue peaked around $1.1 billion in 2012 (Source: EvaluatePharma).
• Competitive Environment: Competed mainly against boceprevir, another protease inhibitor.

B. Emergence of Next-Generation Therapies (2014–Present)

• Key Developments:
  • Introduction of all-oral, interferon-free regimens (e.g., sofosbuvir, ledipasvir/sofosbuvir, velpatasvir/voxilaprevir).
  • Significantly higher cure rates (~95%) and shorter treatment durations.
  • Reduced side effect profiles.
• Impact on INCIVEK:
  • Rapid decline in market share.
  • Market exclusivity eroded; eventually led to withdrawal.

C. Regulatory and Commercial Policies

Policy/Regulation	Impact
FDA Approval (2011)	Enabled initial access and market entry.
Market Withdrawal (2014)	Decision driven by declining sales and strategic shift to newer products.
Patent Expiry	Patent expiration was a determining factor in revenue decline; no further extensions pursued.
Pricing Strategies	Reduced pricing in post-approval years to maintain competitiveness against new therapies.

---

3. Investment Scenario for INCIVEK / Telaprevir Post-Withdrawal

A. Market Value at Peak and Decline

Year	Estimated Global Sales	Source/Notes
2012	~$1.1 billion	EvaluatePharma estimates
2013	~$250 million	Rapid decline begins
2014	<$50 million	Market exit announced

B. Current Investment Outlook

• Market Absence: The commercial market for INCIVEK no longer exists; thus, direct investment in the drug is not feasible.
• Legacy and Patent Considerations: Patent expiration diminishes its value, with generic manufacturers free to produce PSA (patent challenge potentials exist in some jurisdictions).
• Strategic Acquisition or Licensing: Potential in acquiring rights for research, combination with new agents, or generics.
• Research and Development (R&D): Focus shifted to newer HCV agents and hepatitis drugs (e.g., NS5A inhibitors, pan-genotypic agents).

C. Valuation Metrics

Aspect	Details
Market Cap at Peak	Estimated $8–10 billion (Vertex's market cap at IPO)
Current Status	No active commercialization; valuation based on legacy patents and pipeline assets.
Investment Risks	Patent expiry, market obsolescence, regulatory changes, competition from newer therapies.

---

4. Market Dynamics of HCV Therapeutic Market

Factor	Effect
Innovation	Rapidly evolving with new DAAs shifting market focus.
Pricing	Lower prices for generics, variable across regions.
Regulatory Policies	Variations in approvals and reimbursement policies influence market access.
Patent Expiry	Over 75% of early HCV drugs' patents expired between 2015–2020, opening generic markets.
Market Consolidation	Major pharma players (Gilead, AbbVie, Merck) dominate, marginalizing older therapies.

A. Market Share Evolution

Year	Market Share (Estimated)	Major Players
2011	100% (initial launch)	Vertex Pharmaceuticals
2013	<10%	Gilead, Bristol-Myers Squibb, AbbVie
2021	Nominal	Gilead, AbbVie, Merck

B. Financial Trajectory

Stage	Revenue Generation	Investment Implication
Pre-2012	Rapid growth	High ROI, high risk of obsolescence
2012–2014	Peak revenues	High valuation but declining swiftly
Post-2014	Zero (market withdrawal)	Investment in R&D or generics, residual patent/licenses

---

5. Comparison with Competing Agents

Agent	Mechanism	Market Status	Current Relevance
Incivek (Telaprevir)	Protease inhibitor	Withdrawn	None
Victrelis (Boceprevir)	Protease inhibitor	Discontinued	Limited generic presence
Sofosbuvir (Harvoni)	NS5B polymerase inhibitor	Dominant	Continued high relevance
Velpatasvir/ voxilaprevir	Pan-genotypic	Emerging	High growth potential

---

6. Financial Trajectory Forecasts

Forecast Year	Market Size (Post-Withdrawal)	Potential Value	Notes
2023	Minimal	<$50 million for residual patents/licensing	Focus on generics or licensing royalties
2025	<$10 million	Diminishing returns	Patent expirations and generic proliferation
2030 and beyond	Negligible	Low or zero	Complete obsolescence unless repositioned

---

7. Strategic Considerations for Investors

Aspect	Key Point
Patent Lifespan	Critical in determining residual value; patents expired or soon to expire.
Pipeline Assets	R&D assets, combination therapies, or research licenses may offer opportunities.
Market Competition	Dominance of newer DAAs likely reduces relevance of older agents.
Regulatory Environment	Policies favoring innovative, patent-protected drugs influence valuation.
Potential Opportunities	Entry in generic manufacturing, licensing, or combination with next-gen agents.

---

8. FAQs

Q1: Can investors still profit from INCIVEK?

A: Direct investment is not feasible as the product is withdrawn and obsolete commercially. Opportunities exist in licensing residual patents, acquiring generic rights, or investing in pipeline assets.

Q2: What led to the decline of INCIVEK sales?

A: The advent of highly effective, interferon-free, all-oral regimens with superior cure rates and fewer side effects rendered INCIVEK and similar agents obsolete, leading to rapid market decline.

Q3: Are there any ongoing patent protections or licensing opportunities for telaprevir?

A: Patent protections have largely expired; licensing opportunities are limited to residual patent rights, research collaborations, or generics.

Q4: How does the market for HCV treatment look today?

A: Dominated by highly effective, pan-genotypic, interferon-free therapies; the market is mature with high cure rates and expanding into underserved demographics.

Q5: What lessons can investors learn from INCIVEK’s market trajectory?

A: The importance of innovation, patent management, and being adaptable to rapid technological advancements in pharmaceuticals.

---

9. Conclusions and Key Takeaways

• Market Evolution: The hepatitis C therapeutic market transitioned rapidly from protease inhibitors like INCIVEK to all-oral, pan-genotypic regimens.
• Investment Landscape: Since INCIVEK's withdrawal in 2014, direct commercial opportunities have diminished; residual value is primarily in licensing or generics.
• Financial Trajectory: Peak revenues in 2012 (~$1.1 billion) sharply declined, with current market relevance near zero.
• Strategic Focus: Future value hinges on innovation, patent management, pipeline assets, and positioning within the broader HCV market, now dominated by newer treatments.
• Risk Factors: Patent expirations, market obsolescence, and intense competition significantly limit upside potential.

---

References

[1] EvaluatePharma. "HCV Treatment Market and Revenue Data." 2013–2014.
[2] U.S. Food and Drug Administration. "FDA Approval of INCIVEK." 2011.
[3] Vertex Pharmaceuticals. "Financial Reports and Market Data." 2012–2014.
[4] IQVIA (formerly IMS Health). "Global Sales Data for HCV Drugs." 2012–2021.
[5] Gilead Sciences. "Company Reports on HCV Market Strategy." 2021.